Novo Nordisk A/S
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 11 January 2021
– On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.
Under the programme initiated 3 November 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 4 November 2020 to 1 February 2021.
Since the announcement as of 22 December 2020, the following transactions have been made:
|Accumulated, last announcement||4,015,000||1,712,335,766|
|4 January 2021||120,000||431.27||51,752,948|
|5 January 2021||120,000||429.39||51,527,073|
|6 January 2021||120,000||419.48||50,337,361|
|7 January 2021||120,000||421.88||50,625,113|
|8 January 2021||120,000||425.54||51,065,255|
|Accumulated under the programme||4,615,000||1,967,643,517|
The details for each transaction made under the share repurchase programme are published on novonordisk.com .
With the transactions stated above, Novo Nordisk owns a total of 38,138,659 B shares of DKK 0.20 as treasury shares, corresponding to 1.6% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 8 January 2021, Novo Nordisk has since 5 February 2020 repurchased a total of 38,200,522 B shares at an average share price of DKK 424.89 per B share equal to a transaction value of DKK 16,231,072,987.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com , Facebook , Twitter , LinkedIn , YouTube .
|Anne Margrethe Hauge||+45 3079 email@example.com|
|Michael Bachner (US)||+1 609 664 firstname.lastname@example.org|
|Daniel Muusmann Bohsen||+45 3075 email@example.com|
|Valdemar Borum Svarrer||+45 3079 firstname.lastname@example.org|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com|
|Mark Joseph Root||+45 3079 firstname.lastname@example.org|
|Kristoffer Due Berg (US)||+1 609 235 email@example.com|
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Montreal Heart Institute23.1.2021 07:02:08 CET | Press release
Colchicine reduces the risk of COVID-19-related complications
Zealand Pharma22.1.2021 22:06:25 CET | Press release
Zealand Pharma announces update to 2020 financial guidance
Sveriges Riksbank22.1.2021 20:35:53 CET | Press release
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS
Waturu Holding A/S22.1.2021 19:49:42 CET | Press release
Waturu Holding A/S – convening of an extraordinary general meeting
Waturu Holding A/S22.1.2021 19:49:41 CET | Pressemeddelelse
Waturu Holding A/S – indkaldelse til ekstraordinær generalforsamling
Waturu Holding A/S22.1.2021 19:39:41 CET | Press release
Waturu Holding A/S – change in board of directors
Waturu Holding A/S22.1.2021 19:39:40 CET | Pressemeddelelse
Waturu Holding A/S – ændring i bestyrelsen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom